Table 2. Description of tamoxifen knowledge and psychological data.
Mean (± SD) for continuous variables; % (95% CI) for categorical variables | ||
---|---|---|
Baseline (n= 408) | n | |
Received a leaflet about tamoxifen | ||
Yes | 71.1 (66.4, 75.4) | 290 |
No | 25.7 (21.6, 30.3) | 105 |
Unsure | 3.2 (1.7, 5.4) | 13 |
Knowledge | ||
Potential benefit and harms of using tamoxifen + | ||
Yes | 15.7 (12.2, 19.7) | 60 |
No | 84.3 (80.3, 87.8) | 323 |
Missing, n | 25 | |
Tamoxifen can reduce breast cancer risk | ||
Yes | 60.9 (55.8, 65.7) | 238 |
No | 39.1 (34.3, 44.2) | 153 |
Missing, n | 17 | |
Tamoxifen can increase risk of menopausal symptoms | ||
Yes | 50.1 (45.1, 55.2) | 197 |
No | 49.9 (44.8, 54.9) | 196 |
Missing, n | 15 | |
Tamoxifen can increase risk of blood clotting | ||
Yes | 49.7 (44.7, 54.8) | 193 |
No | 50.3 (45.2, 55.3) | 195 |
Missing, n | 20 | |
Tamoxifen can increase risk of endometrial cancer | ||
Yes | 27.3 (22.9, 32.0) | 107 |
No | 72.7 (68.0, 77.1) | 285 |
Missing, n | 16 | |
Satisfaction with healthcare professional, mean ± SD | 19.30 (3.77) | 375 |
Missing, n | 33 | |
Felt informed about tamoxifen | ||
Yes | 87.1 (83.4, 90.2) | 351 |
No | 12.9 (9.8, 16.6) | 52 |
Missing, n | 5 | |
Three month follow-up (n = 258) | ||
Subjective decisional quality, Mean ± SD | 17.03 ± 1.87 | 146 |
‘Still deciding’, n | 111 | |
Missing, n | 1 |
Key: CI, Confidence Interval; SES, Socioeconomic status; SD, Standard deviation.
+= This variable included the potential benefit of tamoxifen (a reduction in breast cancer risk) and three potential harms of tamoxifen (increased risk of menopausal symptoms, blood clotting and endometrial cancer).